Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3978/j.issn.2072-1439.2015.10.73 http://scihub22266oqcxt.onion/10.3978/j.issn.2072-1439.2015.10.73 C4669299!4669299 !26716048     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26716048 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Thorac+Dis 2015 ; 7 (11 ): E522-5 Nephropedia Template TP {{tp|p=26716048 |t=2015. Current and emerging treatments for severe asthma |pdf=|usr=}}{{26716048 }} gab.com Text Current and emerging treatments for severe asthma JO: J Thorac Dis http://www.kidney.de/pget.php?&tw=1&pmid=26716048 #FOAvip Severe asthma, which is poorly controlled despite the elimination of modifiable factors and the correct use of standard therapy, accounts only for 5% of people with asthma but it contributes to approximately 50% of the economic costs of asthma. Because of this unmet need, novel therapies have been developed for optimal treatment of these patients. The use of tiotropium, omalizumab, mepolizumab and thermoplasty in well-selected patients provides better control and most importantly a reduction in asthma exacerbations. Twit Text FOAVip Current and emerging treatments for severe asthma ????J Thorac Dis http://www.kidney.de/pget.php?&tw=1&pmid=26716048 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26716048 #FOAvip English Wikipedia <ref>{{Cite pmid|26716048 }}</ref> Current and emerging treatments for severe asthma #MMPMID26716048 Al Efraij K ; FitzGerald JM J Thorac Dis 2015[Nov]; 7 (11 ): E522-5 PMID26716048 show ga Severe asthma, which is poorly controlled despite the elimination of modifiable factors and the correct use of standard therapy, accounts only for 5% of people with asthma but it contributes to approximately 50% of the economic costs of asthma. Because of this unmet need, novel therapies have been developed for optimal treatment of these patients. The use of tiotropium, omalizumab, mepolizumab and thermoplasty in well-selected patients provides better control and most importantly a reduction in asthma exacerbations. äCurrent and emerging treatments for severe asthma (epmc).pdf DeepDyve Pubget Overpricing